In SURPASS 4 The risk of suffering from any major adverse cardiovascular event MACE-4 and MACE-3 (including myocardial infarction, stroke, hospitalization for angina, and all-cause death) with the highest dose of tirzepatide (15 mg per week) has been estimated at 050 (026095), which was intended to provide initial proof of the cardiovascular safety of tirzepatide [2, 5]
Jger, R., Kerksick, C
Synergistic Tissue Remodeling The GLOW protocol targets tissue remodeling from multiple angles simultaneously
Main Research Findings 1) Administration of GLP-3R has been shown to effectively improve body weight and instances of diabetic kidney diseases, while also inhibiting the expression of various inflammatory factors
Results usually take 24 weeks of consistent use, especially when combined with proper diet and exercise
Lifestyle optimisation In line with NICE NG49, are dietary and physical activity interventions being maximised alongside any pharmacological approach